Targeting tyrosine-kinases in ovarian cancer

Matteo Morotti, Christian M. Becker, Mario Valenzano Menada, Simone Ferrero

Research output: Contribution to journalArticle

Abstract

Introduction: Epithelial ovarian cancer (EOC) is the leading cause of gynaecologic cancer death. Although in some cases initial treatment is effective, most of the women diagnosed with EOC will probably need medical treatment for their disease. There is a critical need to develop effective new strategies for the management of patients with advanced or recurrent EOC, and targeted therapy with tyrosine kinase inhibitors (TKIs) has continued to be an area of active research and development in this setting. Areas covered: This review summarises the available evidence on the use of TKIs in the clinical management of women with EOC. This article consists of material obtained via Medline, PubMed and EMBASE literature searches up to March 2013. Expert opinion: Several Phase I/II and III trials evaluated TKIs in EOC; however, it is difficult to draw conclusions on the efficacy of TKI regimens in these patients. TKIs seem to be better tolerated than conventional chemotherapy with a different toxicity profile. A better understanding of the signalling pathways, the toxicity profiles, the potential pharmacokinetic interactions as well as the identification of predictive biomarkers are needed to better identify a targeted patient population before these agents become part of routine treatment.

Original languageEnglish
Pages (from-to)1265-1279
Number of pages15
JournalExpert Opinion on Investigational Drugs
Volume22
Issue number10
DOIs
Publication statusPublished - Oct 2013

    Fingerprint

Keywords

  • Angiogenesis
  • Ovarian cancer
  • Targeted therapy
  • Tyrosine kinase inhibitor
  • Tyrosine kinases

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this